Skip to main content
. 2021 Dec 17;12:750675. doi: 10.3389/fgene.2021.750675

TABLE 2.

Past and present phase II/III clinical trials with vaccines in glioblastoma.

Clinical trial Duration Phase Target/Lysate Treatment Control Indication Outcome References
NCT01498328 ReACT 2011–2016 II EGFRvIII Bevacizumab + Rindopepimut (n = 33) Bevacizumab + KLH (n = 35) rGBM PFS-6months: 27 vs 11% (Reardon et al., 2015)
NCT00458601 ACT III 2007–2016 II EGFRvIII SOC + Rindopepimut + GM-CSF (n = 65) None ndGBM PFS-5.5 months: 66% (Schuster et al., 2015)
NCT01480479 ACT IV 2011–2016 III EGFRvIII Rindopepimut + GM-CSF + TMZ (n = 371) KLH + TMZ (n = 374) ndGBM OS: 20.1 vs 20 months (Weller et al., 2017)
NCT00643097 ACTIVATe 2007–2016 II EGFRvIII PEP-3-KLH conjugate + GM-CSF (n = 18) TMZ (n = 17) ndGBM PFS-6 months: 67% (Sampson et al., 2010)
NCT01920191 2013–2016 II TAA SOC + IMA950/poly-ICLC (n = 19) None ndGBM OS: 19 months (Migliorini et al., 2019)
NCT00766753 2006–2016 II TAA αDC1 + poly-ICLC (n = 22) None rGBM PFS-12 months: 40.9% (Okada et al., 2011)
NCT02078648 2014–2018 II TAA SL-701 + poly-ICLC + bevacizumab (n = 74) None rGBM OS-12: 37% (Peereboom et al., 2018)
NCT00293423 2013–2017 II Autologous peptides HSPPC-96 (n = 41) None rGBM OS-6 months: 90.2% (Bloch et al., 2014)
NCT00905060 2009–2014 II Autologous peptides HSPPC-96 + TMZ (n = 46) None ndGBM OS: 23.8 months (Bloch et al., 2017a)
NCT01814813 2013–2017 II Autologous peptides HSPPC0-96 + bevacizumab (n = 59) Bevacizumab (n = 31) rGBM OS: 7.5 vs 10.7 months (Bloch et al., 2017b)
NCT00045968 2006–2016 III Tumor lysate DCVax-L + TMZ (n = 232) Autologous PBMC + TMZ (n = 99) ndGBM PFS-2 months: 46.2% PFS-3 months: 25.4% (Liau et al., 2018)